单孔机器人辅助单纯前列腺切除术的初步体会  

Short-term study of robotic single-port laparoscopic simple prostatectomy

作　　者：葛旻垚[1] 徐东亮 翟新宇[1] 万众 谈鸣岳 GE Minyao;XU Dongliang;ZHAI Xinyu;WAN Zhong;TAN Mingyue(Department of Urology Center,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,201203,China)

机构地区：[1]上海中医药大学附属曙光医院泌尿中心,上海201203

出　　处：《临床泌尿外科杂志》2022年第1期29-33,共5页Journal of Clinical Urology

摘　　要：目的:探讨单孔机器人辅助单纯前列腺切除术(spRASP)治疗良性前列腺增生(BPH)的可行性及临床应用价值。方法:回顾性分析2020年11月—2021年6月上海中医药大学附属曙光医院泌尿中心7例采用spRASP治疗BPH患者的临床资料。平均年龄(67±9)岁。经估算的平均前列腺体积(78.3±12.9)mL;平均残余尿(PVR)(58.0±24.8)mL;平均国际前列腺症状评分(IPSS)(20.9±5.9)分,平均生活质量评分(QOL)(4.7±1.5)分,平均最大尿流率(Q_(max))(7.9±3.6)mL/s。比较患者术前和术后3个月的IPSS评分、QOL评分、PVR、Q_(max)、IIEF等差异,分析评价手术疗效。结果:7例手术均顺利完成。平均手术时间(85.5±25.5)min,平均估计出血量(75.5±25.5)mL,平均留置引流管时间(3.4±0.8)d,平均留置尿管时间(7.5±1.2)d,术后平均住院时间(5.1±3.1)d。术后3个月患者平均IPSS评分(10.8±3.1)分、平均QOL评分(1.6±0.9)分、平均PVR(15.3±4.6)mL,与术前比较均明显降低(P<0.05),平均Q_(max)(24.4±11.6)mL/s与术前比较明显升高(P<0.05),IIEF与术前比较差异无统计学意义(P>0.05)。结论:spRASP是治疗BPH患者安全、有效的方法。Objectives:To assess the feasibility and efficacy of single-port robot assisted simple prostatectomy(spRASP)for the treatment of benign prostatic hyperplasia(BPH).Methods:From November 2020to June 2021,7patients with BPH were treated by spRASP in the urology center of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine.The average patients'age was(67±9)years.The estimated prostate volume was(78.3±12.9)mL;preoperative residual urine volume was(58.0±24.8)mL;the average International Prostate Symptoms Score(IPSS)was(20.9±5.9)scores,the average Quality of Life Score(QOL)was(4.7±1.5)scores,the average maximum urine flow rate(Q_(max))was(7.9±3.6)mL/s,respectively.All patients agreed to accept spRASP.The pre-operative and three months post-operative IPSS,QOL,residual urine and Q_(max) were compared and analyzed.Results:All seven patients were successfully completed.The average operation time was(85.5±25.5)min,the average estimated blood loss was(75.5±25.5)mL,drainage time was(3.4±0.8)days,catheterization time was(7.5±1.2)days,postoperative hospital stay was(5.1±3.1)days.Three months after surgery,patient's IPSS was(10.8±3.1)scores,QOL was(1.6±0.9)scores,the average residual urine was(15.3±4.6)mL and Q_(max) was(24.4±11.6)mL/s,respectively.All the parameters significantly improved compared with the preoperative data(P<0.05).Conclusion:spRASP is a safe and effective treatment for patients with BPH.

关 键 词：单孔机器人手术 腹腔镜 梅迪根 良性前列腺增生 前列腺切除术 

分 类 号：R697[医药卫生—泌尿科学]